Status:
RECRUITING
Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations
Lead Sponsor:
Boston Children's Hospital
Collaborating Sponsors:
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
PTEN
ASD
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine cross-sectional and longitudinal medical, behavioral, and cognitive differences between PTEN ASD and other groups, as well as to identify cognitive, neural sy...
Detailed Description
Autism spectrum disorders (ASD) are a set of neurodevelopmental disorders characterized by social communication/interaction impairments and restricted/repetitive behaviors. ASD associated with germlin...
Eligibility Criteria
Inclusion Criteria
- Individuals above the age of 18 months old at the time of consent who have documentation of a clinical diagnosis of autism spectrum disorder and/or a verified PTEN mutation from a medical or mental health professional for inclusion in the PTEN ASD, PTEN no-ASD or ASD macrocephaly groups.
- Macrocephaly (head circumference greater than or equal to 98th percentile) for inclusion in the ASD macrocephaly group.
- For youths, consent from parents or legal guardian. For adults, consent from self or legal guardian.
- Youths who are able (some young or severely impaired participants may not be able to provide assent) will be asked to provide assent as per IRB guidelines.
- Families with multiple children who meet the above inclusion criteria will be permitted to have as many children participate as they wish. A separate consent form will be filled out for each child enrolled in the study.
- Primary communicative language must be English
Exclusion Criteria
- Unwilling or unable to comply with study procedures and assessments
- Clinically significant medical disease that would prohibit participation in the study procedures.
- For subjects ELIGIBLE FOR OPTIONAL imaging biomarker assessment: contraindications to 3T MRI scanning, such as metal implants/non-compatible medical devices or medical conditions, including vagus nerve stimulator.
- For subjects ELIGIBLE FOR EEG/ERP biomarker assessment: contraindications to EEG/ERP, such as uncooperative or destructive behaviors preventing lead placement or capture by ERP/VEP equipment. Under age 2 or over 11 at the time of enrollment.
Key Trial Info
Start Date :
May 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT02461446
Start Date
May 1 2015
End Date
December 1 2026
Last Update
October 26 2024
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California at Los Angeles
Los Angeles, California, United States, 90095
2
Stanford University Medical Center
Stanford, California, United States, 94305
3
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
4
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229